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ABSTRACT  
Background:  Most studies of post-transplant CMV infection have focused on 
either solid organ or hematopoietic cell transplant (HCT) recipients. A large 
prospective cohort study involving both lung and HCT recipients provided an 
opportunity to compare the epidemiology and outcomes of CMV infections in 
these two groups.  Methods:  Patients were followed for 30 months in a 6-center 
prospective cohort study. Data on demographics, CMV infections, tissue-invasive 
disease, recurrences, rejection, and immunosuppression were 
recorded.  Results: The overall incidence of CMV infection was 83/293 (28.3%) in 
the lung transplant group and 154/444 (34.7%) in the HCT group (p = 0.0706). 
Tissue-invasive CMV disease occurred in 8/83 (9.6%) of lung and 6/154 (3.9 %) 
of HCT recipients with CMV infection, respectively (p=0.087).  Median time to 
CMV infection was longer in the lung transplant group (236 vs. 40 days, p < 
0.0001), likely reflecting the effects of prophylaxis vs. pre-emptive therapy. Total 
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IgG levels of < 350 mg/dl in lung recipients and graft versus host disease (GvHD) 
in HCT recipients were associated with increased CMV risk. HCT recipients had 
a higher mean number of CMV episodes (p=0.008), although duration of viremia 
was not significantly different between the two groups. CMV infection was not 
associated with reduced overall survival in either group.  Conclusions:
 
 Current 
CMV prevention strategies have resulted in a low incidence of tissue-invasive 
disease in both lung transplant and HCT, although CMV viremia is still relatively 
common. Differences between the lung and HCT groups in terms of time to CMV 
and recurrences of CMV viremia likely reflect differences in underlying host 
immunobiology and in CMV prevention strategies in the modern era.  
INTRODUCTION 
 
Although there is extensive literature on CMV and CMV prevention in 
transplantation (1-5), most studies have focused on either solid organ 
transplantation or HCT alone, and have rarely compared these two groups in 
terms of CMV incidence, risk factors, virologic features, and outcomes. The 
Organ Transplant Infection Prevention (OTIP) study is a 6-center cohort study 
involving lung transplant and HCT recipients with parallel data collection 
methodologies. Although originally established for the purpose of investigating 
the epidemiology and environmental risk factors for post-transplant fungal 
infections, the OTIP study design has provided a unique opportunity for 
comparing and contrasting various other infections in these two groups (6). The 
current study focuses specifically on CMV infections in the OTIP cohort.  
 
METHODS  
During 2006-11, six academic transplant centers  (University of Pittsburgh, 
University of Alabama at Birmingham, University of Michigan, Washington 
University, University of Pennsylvania, and Cleveland Clinic),  contributed 
patients (5 centers for lung transplant recipients and 4 centers for HCT 
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recipients).  All patients provided written informed consent, and Institutional 
Review Board approval was obtained at each center.  Detailed questionnaires 
were administered to each patient at baseline. Clinical assessments were 
performed weekly during the transplant admission and subsequent 
hospitalizations. After discharge, patients were contacted by phone weekly for 
the first 12 weeks post-transplant, and monthly after that, with a total follow-up 
period of up to 30 months. Infectious syndromes were defined according to 
National Nosocomial Infections Surveillance System criteria (7). A uniform case 
report form and electronic data entry form developed by the Centers for Disease 
Control and Prevention (CDC) was used by all centers, and information was 
forwarded to a central data repository at CDC.   
 
Definitions of tissue-invasive CMV disease (end-organ disease) and CMV 
viremia followed the standard definitions that were in use at the time of the study 
(8).  Although subsequently updated definitions have been published (9), which 
should now replace the older definitions for clinical trials, the newer definitions 
were not yet published at the time this study was conducted.  Therefore, “tissue-
invasive CMV” indicated positive histopathology or a positive CMV immunostain 
on a tissue biopsy (except for CMV retinitis, which was diagnosed by 
ophthalmologic examination).  “CMV viremia” was defined as any detection of 
CMV in blood by CMV quantitative polymerase chain reaction (CMV PCR) or 
pp65 antigenemia testing. For purposes of this study, data were not collected on 
the intermediate category of “CMV syndrome” which has been defined for solid 
organ transplant, but not HCT recipients (8,9), and in the current study, such 
patients were categorized as having CMV viremia rather than tissue-invasive 
disease, even if symptomatic.  A CMV episode was considered resolved if the 
CMV PCR or antigenemia test was negative (undetectable) twice, on assays 
obtained at least 1 week apart, and a recurrence was defined as any CMV 
detection that occurred after at least 2 negative (undetectable) PCR or 
antigenemia test results had been obtained.  
Definitions 
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CMV viral load monitoring was performed per each center’s protocol. Most 
centers used CMV quantitative PCR assays during this time period, which was 
before the advent of the United States Food and Drug Administration (FDA)-
approved PCR assay in IU/mL; therefore, CMV PCR assays were center-specific 
with results expressed as DNA copies/ml. A study core lab was not utilized in this 
study; therefore, CMV PCR measurements were not standardized among 
centers (10). One center used only pp65 antigenemia assays, and two centers 
used both pp65 antigenemia assays and CMV PCR assays. Shell vial cultures 
for CMV were performed on bronchoalveolar lavage fluid per center protocol. 
Duration of CMV prophylaxis and use of pre-emptive strategies are described in 
the Results section below.  
CMV Detection Assays 
 
Data collected by the six OTIP centers was transmitted to CDC via an electronic 
case report form. Data were collected in real time and forwarded at least monthly.  
Final data cleaning and statistical analysis were performed at the CDC. Chi-
square and Fisher’s exact tests, as appropriate, were used to compare 
categorical variables, and t-tests and Wilcoxon rank-sum tests were used to 
compare continuous variables. In all analyses, the level of significance was set at 
α=0.05. All analyses were done using SAS software (version 9.3, SAS Institute, 
Inc., Cary, NC).   
Statistics and Data Analysis 
 
RESULTS   
Demographics and pre-transplant characteristics of the study patients are 
summarized in Tables 1 and 2. There were 293 lung transplant recipients from 5 
centers (University of Pittsburgh 174, University of Michigan 43, University of 
Alabama 38, Cleveland Clinic 33, and University of Pennsylvania 5); , and 444 
HCT recipients from 4 centers (Washington University 207, University of 
Patients and Pre-transplant Characteristics 
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Michigan 153, University of Pennsylvania 60, University of Alabama 24). The 
patients were not evenly distributed among centers; one transplant center 
(University of Pittsburgh) accounted for 59.4% of the lung transplant recipients, 
and two transplant centers (Washington University and University of Michigan) 
accounted for 46.6% and 34.5% of the HCT recipients, respectively.  Transplant 
types, underlying diagnoses, pre-transplant conditioning and induction 
immunosuppression agents, CMV serostatus and prevention strategies are 
summarized in Tables 1 and 2. 
 
In the lung transplant cohort, 72/293 (24.6%) were in the high-risk CMV donor-
seropositive, recipient-seronegative (D+/R-) group. In the HCT cohort, 94/444 
(21.2%) were in the high-risk CMV donor-seronegative, recipient-seropositive 
group (D-/R+).   
 
The overall incidence of CMV infection was 83/293 (28.3%) in the lung transplant 
group and 154/444 (34.7%) in the HCT group (p = 0.0706). Tissue-invasive (end-
organ) CMV disease occurred in 8 lung transplant recipients (9.6% of those with 
CMV infection) and 6 HCT recipients (3.9% of those with CMV infection, p=0.8.) 
Of 24 lung recipients with positive CMV shell vial BAL cultures, 7 (30%) had CMV 
pneumonitis and 17 (70%) did not (representing viral shedding without tissue-
invasive disease.) 
Overall Incidence of CMV Infection and Risk Factors for CMV  
 
In the lung transplant group, none of the characteristics listed in Table 1 was 
significantly associated with risk for CMV. In the HCT group, 11/15 (73.3%) of 
African-American patients and 5/5 (100%) of Asian patients developed CMV, as 
compared with 137/421 (32.7%) of Caucasian patients, but given the small 
number of non-Caucasian patients, this should be considered a questionable 
finding.  There was a difference among centers in terms of CMV incidence for the 
HCT group (p = 0.0009), paralleling the percentages of unrelated donors at the 
four HCT centers (which ranged from 46% - 68% unrelated donor HCT’s), 
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although a formal analysis of other factors contributing to center-specific 
differences was not performed. There were no center-specific differences in CMV 
incidence in lung transplant recipients. Mismatched unrelated donor HCT 
recipients had the highest risk, in that 12/20 (60%) of that group developed CMV 
infection, as compared with 57/177 (32.2%) of matched related donor and 85/245 
(34.7%) of matched unrelated donor HCT recipients (p = 0.066), but the number 
of mismatched unrelated donor HCT’s in this study was small (20/444 or 4.5%). 
There was no significant difference in CMV risk between HCT recipients who 
received myeloablative or nonmyeloablative regimens.  
 
No peritransplant immunosuppressive regimens, including alemtuzumab 
induction, were significantly associated with CMV risk in lung transplant 
recipients.  In the HCT group, the use of antithymocyte globulin (ATGAM) 
approached significance, in that 20/42 (47.6%) of ATGAM-treated patients 
developed CMV (p=0.0642). Use of methotrexate for GVHD prophylaxis in HCT 
recipients was associated with a lower risk of CMV, with an odds ratio of 0.520 
(95% CI, 0.313 – 0.864).  None of the other immunosuppressive medications 
were associated with differential risk for CMV.  
 
Rejection episodes occurred in 72% of lung transplant recipients, but rejection 
was not significantly associated with CMV in this group. GVHD (of any site or 
grade) occurred in 76.4% of HCT recipients overall, and occurrence of any 
GVHD was associated with CMV with an odds ratio of 1.627 (95% CI, 1.001  – 
2.643).  
 
Total immunoglobulin G (IgG) levels were checked (per clinician preference) in 
30.7% of lung transplant recipients, and 18.9% of those who had IgG’s checked 
had very low levels (< 350 mg/dl); There was no association between CMV and 
IgG levels in lung recipients overall, but those with an IgG level of < 350 mg/dl 
had a higher incidence of CMV infection (p=0.0424). Total IgG levels were 
checked in 300/444 (67.6%) of HCT recipients, and there was no association 
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between IgG levels and CMV risk, despite 35.7% of those who had IgG checked 
having a low nadir IgG level (< 350 mg/dl).  
 
In the lung transplant group, the highest risk for developing CMV infection was in 
the donor seropositive/recipient seronegative (D+/R-) group, in which 30/72 
developed CMV (41.7%), followed by the D+/R+ (33/90, or 36.7%), D-/R+ (8/50, 
or 16%) and  D-/R- (2/49, or 4.1%) groups.  Twenty-eight donors and 13 
recipients had missing serologic information.  
Donor and Recipient Serostatus and CMV Risk  
 
In the HCT group, the highest risk for developing CMV infection was in the donor 
seronegative, recipient seropositive (D-/R+) group, in which 53/94 (56.4%) 
developed CMV, followed by the D+/R+ (51/95, or 53.4%),  D+/R- (5/39, or 
12.8%) and D-/R- (19/157, or 12.1%) groups.  Fifty-five donors and 26 recipients 
had missing serologic information. 
 
 
CMV Prophylaxis Duration, CMV Incidence, and Time to CMV 
CMV prophylaxis using valganciclovir was administered to 267/293 (91.1%) of 
lung recipients, and 48 (16.4%) received IV ganciclovir as part of prophylaxis.  
The median length of CMV prophylaxis was 178 days (range, 1–977).  Acyclovir 
was administered to 63 (21.5%) and valacyclovir to 5 (1.7%), generally to those 
who were CMV D-/R-, for prophylaxis of herpes simplex virus (HSV) and 
varicella-zoster virus (VZV).   Only 7 (2.4%) of lung transplant recipients received 
CMV immune globulin (CMVIg) for any indication.  
 
In contrast, HCT recipients in general did not receive prophylaxis against CMV, 
but instead were managed with a strategy of serial monitoring of CMV PCR or 
pp65 antigenemia assays usually through Day 100 post-transplant,  and pre-
emptive therapy when the CMV PCR or antigenemia assay turned positive.  HCT 
recipients generally received prophylaxis for HSV and VZV in the form of 
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acyclovir (315/444, or 71%) or valacyclovir (183/444, or 41.2%) per their centers’ 
protocols, while undergoing CMV monitoring. In the HCT group, 24 patients 
received CMVIg, but 23 of these had CMV infection (hence CMVIg was not used 
for prophylaxis).   
 
Time to first detection of CMV was significantly different between lung transplant 
recipients with a median of 236 days (range, 4–689) and HCT recipients with a 
median of 40 days (range, 4–666; p < 0.0001). Twelve HCT patients (7.7%) 
developed CMV infection prior to engraftment.  In the lung transplant group, 20 
patients (27% of those with CMV infection) developed their first CMV episode 
while still on anti-CMV prophylaxis.  
 
Tissue-invasive CMV disease (end-organ disease) was uncommon in this cohort, 
occurring in 8/83 (9.6%) of lung recipients with CMV, or 8/293 (2.7%) of all lung 
recipients, and 6/155 (3.9%) of HCT recipients with CMV, or 6/444 (1.4%) of all 
HCT recipients (p=0.087). Sites of end-organ involvement in lung recipients 
included CMV pneumonitis in 7, CMV colitis in 2, and other sites in 2, whereas 
sites in HCT recipients included CMV enterocolitis in 4, CMV pneumonitis in 1, 
and CMV hepatitis in 1.  
CMV Clinical and Virologic Features 
 
Recurrences of CMV occurred in 18/83 (21.7%) of lung transplant recipients and 
65/154 (42.2%) of HCT recipients (p=0.0016). The mean number of CMV 
episodes was significantly higher in HCT recipients, with 1.63 CMV episodes per 
patient (range, 1-5 episodes) as compared with lung transplant recipients, who 
had a mean of 1.34 CMV episodes per patient (range, 1-4 episodes, p =  
0.0076.)   Information on duration of viremia was available for 166/237 (70% ) of 
the patients with CMV episodes, and the median duration was 46.5 days for lung 
transplant recipients (range,  1–405 days) versus 41 days for HCT recipients 
(range, 1–900 days), which was not significantly different (p =0.5612). 
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Fungal infections occurred in 24 lung transplant recipients (8.2%) and 48 HCT 
recipients (10.8%), with no significant differences in fungal infection incidence 
between the groups who did and did not develop CMV infection.  
 
Antiviral agents other than ganciclovir and acyclovir derivatives were 
administered to relatively few lung recipients (6 foscarnet, 2 cidofovir, all of whom 
were in the group that developed CMV infection) and relatively more HCT 
recipients (40 foscarnet, 29 cidofovir).  The specific reasons for choice of antiviral 
agent were not recorded in this dataset. Among HCT recipients, 8 foscarnet and 
11 cidofovir recipients were in the group that never developed CMV viremia, so 
these antiviral agents may have been administered for treatment of other viruses 
(e.g. HSV, VZV, HHV-6, BKV, or adenovirus infection). In addition, it is possible  
that some foscarnet use in the HCT group with CMV (32 patients) might have 
reflected clinicians’ desire to avoid the hematologic toxicities of 
ganciclovir/valganciclovir in patients with pre-engraftment CMV or borderline 
neutropenia. 
 
 
Overall survival in this cohort at 6, 12, and 18 months was 89.4%, 82.9%, and 
80.6% for lung transplant recipients, and 72.3%, 59.2%, and 54.3% for HCT 
recipients. There was no significant reduction in survival in either cohort between 
those who developed CMV infection and those who did not.  
Survival 
 
DISCUSSION  
The results of this large multicenter cohort study highlight both the differences in 
host immunobiology, and also the effects of different antiviral prevention 
strategies between lung transplant and HCT recipients.  This study demonstrates 
that CMV viremia remains common in both types of transplant recipients in the 
modern era, although tissue-invasive CMV disease has become uncommon with 
the use of current CMV prevention strategies (1-5).  Since HCT programs rely on 
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pre-emptive monitoring rather than universal antiviral prophylaxis (4-5), it is not 
surprising that CMV viremia remains common in this group, but it also occurred 
in 28.3% of lung recipients despite prophylaxis.  Thus, it appears that the 
success of CMV prevention in both groups has not been in the complete 
suppression of viremia, but rather in the prevention of highly symptomatic CMV 
and end-organ CMV disease.    
 
Recurrences of viremia were more common in HCT recipients than in lung 
transplant recipients, likely reflecting host factors and the requirement for HCT 
recipients to reconstitute their immune system from the donor and concomitantly 
to develop CMV-specific immune function. 
This study confirmed a number of CMV risk factors that have been described in 
previous literature, including the high-risk status of the donor-seropositive, 
recipient-seronegative (D+/R-) group in solid organ transplant recipients and the 
donor-seronegative, recipient-seropositive (D-/R+) group in HCT (1-5).  The 
former reflects the de novo acquisition of donor-transmitted CMV infection in a 
solid organ transplant recipient without antecedent CMV-specific immunity, 
whereas the latter reflects the reconstitution of a donor immune system without 
antecedent CMV-specific immunity in the context of a recipient at risk for 
reactivation of pre-existing latent CMV infection.   This study also confirms that  
the risk of CMV viremia varies with the type of HCT (11), for example higher risk 
in mismatched unrelated HCT recipients, although these constituted only 4.5% of 
HCT recipients in this study.   Cord transplant recipients constituted only a small 
fraction of patients in the current study, precluding meaningful comparisons.  
 
Of note, although the number of patients with tissue-invasive CMV disease in this 
cohort was small, it is interesting to note that the sites of end-organ involvement 
showed a predominance of CMV pneumonitis in lung recipients, and 
gastrointestinal CMV in HCT recipients. Lung recipients have traditionally been 
noted to be at risk for CMV pneumonitis, given the propensity for CMV invasive 
disease to localize to the allograft.   However, the finding that approximately 2/3 
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of lung recipients with positive CMV shell vial cultures from BAL did not have 
documented CMV pneumonitis parallels that of the study of BAL CMV viral loads 
by Chemaly et al, in which detection of CMV without tissue invasion occurred in 
about 2/3 of those with positive BAL CMV cultures, and this shedding was 
associated with lower levels of quantitative BAL viral load.  Therefore a positive 
CMV shell vial culture from BAL does not necessarily indicate CMV pneumonitis 
(12).  
 
One of the original goals of this study was the comparison of infection outcomes 
between centers that do or do not use alemtuzumab induction in lung 
transplantation (13); we found that there was no significant difference in CMV 
infection in relation to alemtuzumab use in this cohort. Of the 
immunosuppressive agents administered, the only significant association was a 
lesser risk of CMV in HCT recipients who received methotrexate for GVHD 
prophylaxis. There was a trend towards increased CMV incidence in HCT 
recipients who received antilymphocyte therapy. Other immunosuppressive 
agents and acute rejection in lung recipients were not associated with differential 
CMV risk in this study. There may still be inherent increased risk associated with 
certain immunosuppressive regimens and with acute rejection, but this risk might 
have been compensated for by heightened awareness and interventions on the 
part of clinicians.   
 
Hypogammaglobulinemia was common in both groups, but was not associated 
with CMV risk in this study, except in lung recipients in the lowest IgG group 
(<350 mg/dL). A previous study of hypogammaglobulinemia in lung 
transplantation had identified low IgG levels as associated with increased risk for 
tissue-invasive CMV disease, although not for CMV viremia in general (14). On 
the other hand, any occurrence of GVHD in this study was associated with 
increased CMV risk in HCT recipients.  
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The effects of different CMV prevention strategies were evident in the time-to-
CMV data.  The standard of CMV prevention in lung transplantation has 
traditionally been prophylaxis using IV ganciclovir and more recently 
valganciclovir.  The randomized trial of 3 vs. 12 months valganciclovir 
prophylaxis by Palmer et al (15), published when the current study was nearly 
completed, demonstrated the benefits of longer durations of prophylaxis in lung 
transplant recipients. Before that, there was already a trend towards longer 
prophylaxis in lung transplant programs, as seen in previous nonrandomized 
trials (16-17).  The median prophylaxis duration of almost 6 months for lung 
transplant recipients in the current study was thus reflective of a shift in practice 
occurring around that time. Therefore it is not surprising that the initial detection 
of CMV viremia occurred much later in lung transplant recipients (“late CMV” 
after completion of prophylaxis) (18), as compared with HCT recipients who 
received pre-emptive monitoring.  
 
CMV infection and its treatment may predispose to fungal infections, either 
through cytopenias or by immunosuppressive effects of CMV itself, but we 
observed no significant difference in frequency of invasive fungal infections in 
patients who did and did not develop CMV in this study.  
A comparison with incidence of CMV disease in other studies, and with historical 
incidence of CMV disease in previous eras, is illuminating.  In the early years of 
lung transplantation, there was a high incidence of CMV pneumonitis and a high 
mortality, particularly in CMV primary infection. For example, in the pre-
prophylaxis era, the incidence of CMV infection was 80%, and CMV disease 
occurred in 31% of all lung recipients (19). In one study, prophylaxis using a 
delayed-ganciclovir regimen reduced these numbers to 48% and 10% 
respectively (19).  The VAL038 study (15),  a randomized controlled trial which 
compared 3 vs 12 months of valganciclovir prophylaxis in lung transplant 
recipients, reported a 32% incidence of CMV disease in the short-course 
prophylaxis group.  The numbers in our current study are closer to those of the 
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long-course prophylaxis group in the VAL 038 study (which had a 4% incidence 
of CMV disease). 
 
In the HCT realm, much of our knowledge comes from the large studies 
performed at the Fred Hutchinson Cancer Research Center (FHCRC).  For 
example, Green et al  reported an incidence of CMV disease of 5.2% in those 
monitored with CMV PCR, and 5.8% in those monitored with antigenemia assays 
(4). In a separate analysis from FHCRC, Erard et al noted an improvement in 
mortality due to CMV pneumonitis in HCT over time (5). Randomized clinical 
trials can also provide insight into background incidence. For example, in the 
placebo group of the Maribavir HCT prophylaxis study, CMV disease occurred in 
5% and CMV infection occurred in 30-37%, depending on assay and excluding 
D-/R- (20). This correlates quite closely with the incidence of CMV infection of 
34.7% in the HCT cohort in our study, although the incidence of tissue-invasive 
disease was somewhat lower in our study, being only 1.4% of total HCT 
recipients (3.9% of those who had CMV viremia).   These differences may reflect 
center-specific protocols for conditioning and GVHD prophylaxis, different case 
mixes and risk profiles of the recipients, different applications of standard 
definitions, or other factors. However, in all 3 of the above studies,  tissue-
invasive disease incidence was relatively low in the current era compared with 
the historical rates from the earlier years of BMT, in which as many as 43% 
developed CMV disease, frequently with CMV pneumonitis which was associated 
with a high mortality (21). Somewhat surprisingly, we observed no association 
between CMV infection and reduction of overall survival in the current study. It is 
possible that other aspects in the modern era of CMV management, such as 
modulation of immunosuppression during and after viremia episodes, could 
theoretically have counterbalanced an adverse impact of CMV on survival.  
 
 
LIMITATIONS 
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This study had several limitations. Patients were not evenly distributed among 
centers, with one center contributing over half of the lung transplant recipients, 
and two centers contributing the majority of the HCT recipients. This was a 
predominantly Caucasian cohort across all 6 centers, and results may not be 
generalizable to other racial/ethnic groups. Some CMV serologies were missing, 
particularly in HCT donors. Centers varied in their use of induction and 
maintenance immunosuppression and antimicrobial prophylaxis. Center-specific 
protocols were used for CMV prevention, and for monitoring of CMV viremia; the 
duration and frequency of monitoring varied, depending on center practices and 
risk stratification. To obtain a truly accurate incidence of CMV viremia, centers 
would have had to adhere to a uniform monitoring protocol; therefore the 
incidence of viremia should be interpreted with this caveat in mind. The CMV 
PCR assays used during this time period differed among centers, as this study 
was performed before the introduction of the FDA-approved CMV PCR assay 
that is now internationally accepted. One center used only pp65 antigenemia 
assays, and two centers used both pp65 antigenemia and PCR over time. It is 
likely that significant inter-laboratory variation existed among the centers using 
quantitative CMV PCR assays (9) and therefore, planned comparisons of CMV 
median and peak viral loads were eliminated from the data analysis plans. 
Thresholds for initiating CMV therapy varied from center to center and within 
centers over time, reflecting changes in assays and in clinical practice. The 
reasons for use of foscarnet and cidofovir were not recorded, including 
resistance genotype testing, therefore precluding observations about antiviral-
resistant CMV. The lack of data collection on the intermediate category of “CMV 
syndrome” in lung transplant recipients may have underestimated the severity of 
symptomatic disease in this group. Finally, the study was not designed to assess 
the impact of infections on bronchiolitis obliterans syndrome or chronic lung 
allograft dysfunction in lung recipients or on graft survival/graft loss in HCT 
recipients, although those issues are of great interest to clinicians.  
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CONCLUSIONS  
 
Despite the limitations noted above, interesting comparisons have emerged 
between multicenter cohorts of lung transplant and HCT recipients in the modern 
era, with regards to CMV incidence, risk factors, clinical and virologic 
characteristics, and patient outcomes. These likely reflect both the disparate 
nature of host responses to CMV, and also prevention strategies that are 
differentially applied to these groups due to the high risk of cytopenias in HCT 
recipients from prolonged use of valganciclovir and ganciclovir. Evidence-driven 
prophylaxis duration has become increasingly longer in lung transplant recipients, 
but pre-emptive monitoring and directed therapy remain the standard in HCT 
recipients. In both groups, the success of prevention strategies is reflected in an 
overall low incidence of tissue-invasive disease (despite a continued incidence of 
viremia) and the lack of a detrimental impact of CMV viremia on survival in both 
groups. Other findings include a significantly earlier onset of CMV viremia in HCT 
recipients, likely related to the use of pre-emptive therapy rather than prophylaxis, 
and also more CMV recurrences in the HCT group. The increased use of 
antivirals other than ganciclovir/valganciclovir in the HCT group with CMV may 
reflect the concerns of HCT clinicians regarding the risk of neutropenia from 
ganciclovir derivatives. Taken together, these results enable us to understand 
how far the field of CMV prevention has come, and also to provide historical 
background for assessments of the impact of new immunosuppressive and 
antiviral agents that may be introduced in the future.  
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TABLE 1. Selected Demographics, Pretransplant and Transplant Features of 
Lung Transplant Recipients With and Without CMV Infection 
Total CMV Infection - CMV infection + p value 
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Overall  293 210 83  
Gender male 168 (57.3%) 121 (57.6%) 47 (56.6%)  0.8770 
Median age, years (range) 58.3 (19.7-81.9)  57.2 (19.7-79.9) 60.1 (20.4-81.9) 0.0869 
Race Caucasian 275 (93.9%) 195 (92.9%) 80 (96.4%) 0.4511 
Underlying disease prompting 
transplant 
   0.5393 
     Cystic fibrosis 39 (13.3%)  32 (15.2%) 7 (8.4%)  
     COPD 95 (32.4%)  63 (30.0%)  32 (38.6%)  
     Idiopathic pulmonary fibrosis 93 (31.7%)  65 (31.0%)  28 (33.7%)   
Type: Bilateral  182 (62.1%) 132 (62.9%) 50 (60.2%) 0.6674 
Alemtuzumab 173 (59.0%) 130 (61.9%) 43 (51.8%) 0.1133 
Basiliximab 17 (5.8%)  15 (7.1%)  2 (2.4%)  0.1662 
Rejection 211 (72.0%) 146 (69.5%)  65 (78.3%) 0.1310 
IgG < 350 mg/dl* 17 (18.9%) 8 (13.1%)  9 (31.0%)  0.0424 
D+/R- 72 (24.6%) 42 (20%) 30 (36.1%) 0.003 
Valganciclovir prophylaxis 267 (91.1%) 189 (90.0%)  78 (94.0%)  0.2809 
 
* Checked in 30.1% of patients per clinician choice. Percentages refer to % of patients in whom 
IgG levels were checked.  
ABBREVIATIONS: COPD – chronic obstructive pulmonary disease, IgG – immunoglobulin G 
 
TABLE 2. Selected Demographics, Pretransplant and Transplant Features of 
Hematopoietic Cell Transplant Recipients With and Without CMV Infection 
Total CMV Infection - CMV infection + p value 
Overall  444 290 154  
Gender male 256 (57.7%) 168 (57.9%) 88 (57.1%) 0.8729 
Median age, years (range) 52.5 (18.3-75.0) 52.3 (18.3-70.5) 52.9(18.7-75.0) 0.4601 
Race Caucasian 421 (94.8%) 284 (97.9%) 137 (89.0%) 0.0002 
Underlying disease prompting 
transplant 
    
     Acute myelogenous leukemia 180 (40.5%) 114 (39.3%) 66 (42.0%)  
     Acute lymphocytic leukemia 41 (9.2%) 30 (10.3%) 11 (7.1%)  
     Non-Hodgkin’s lymphoma 79 (17.8%) 52 (17.9%) 27 (17.5%)  
Type of HSCT    0.0658 
     Matched-related 177 (39.9%) 120 (41.4%) 57 (37.0%)  
     Mismatched-related 2 (0.5%) 2 (0.7%) 0 (0%)  
     Matched-unrelated 245 (55.2%) 160 (55.2%) 85 (55.2%)  
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     Mismatched-unrelated 20 (4.5%) 8 (2.8%) 12 (7.8%)  
Source of cells    0.082 
     BMT 53 (11.9%) 37 (12.8%) 16 (10.4%)  
     PBSCT 386 (86.9%) 252 (86.9%) 134 (87.0%)  
     Cord 5 (1.1%) 1 (0.3%) 4 (2.6%)  
Myeloablative  319 (71.9%) 214 (73.8%) 105 (68.2%) 0.2108 
Conditioning: ATGAM*     
GVHD prophylaxis methotrexate** 100 (22.5%) 76 (26.2%) 24 (15.6%) 0.0108 
Ever had GVHD 339 (76.4%) 213 (73.4%) 126 (81.8%) 0.0482 
IgG < 350 mg/dl*** 107 (35.7%) 59 (32.6%) 48 (40.3%) 0.1589 
D-/R+ 94 (21.2%)  41 (14.1%) 53 (34.4%) <0.0001 
 
*p values for all other conditioning regimen agents were not significant 
**p values for all other GVHD prophylaxis agents were not significant 
***Checked in 67.6% of patients per clinician choice. Percentages refer to % of patients in whom 
IgG levels were checked 
 
ABBREVIATIONS:  BMT – bone marrow transplant, PBSCT – peripheral blood stem cell 
transplant, ATGAM – antithymocyte globulin, GVHD – graft-vs-host disease, IgG – 
immunoglobulin G 
Table 3. Comparison of CMV between lung transplant and HCT recipients 
 
 Lung  HCT p value 
Overall (n, %) 83 (28.3%) 154 (34.7%) 0.0706 
Median time to CMV, days (range) 236 (4-689) 40 (4-666) < 0.0001 
 
CMV recurrence (n, %) 
 
18/83 (21.7%) 65/154 (42.2%) 0.0015 
 
Mean # of CMV episodes (range) 
 
1.34 (1-4) 1.63 (1-5) 0.0076 
 
Median duration of viremia, days 
(range)* 
 
46.5 (1-405) 
 
 
41 (1-900) 
 
0.5612 
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*N=166 patients with information available 
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